Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

MK-3120

Antibody-drug conjugate · Cytotoxic, directed at nectin-4 · developed by Merck &

Phase 1/2 Most advanced trial

MRK Developer

1 Registered trials

What is MK-3120?

MK-3120 is an antibody-drug conjugate composed of an anti-nectin-4 monoclonal antibody linked to KL6100023, a topoisomerase I inhibitor. The antibody binds nectin-4 on tumor cells, delivering the cytotoxic payload to inhibit DNA replication and induce apoptosis. It is studied in urothelial carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Antibody-drug conjugate
Targets: nectin-4, DNA topoisomerase I (TOP1) (secondary target)
Mechanism: Cytotoxic, directed at nectin-4
Pathways: DNA replication inhibition, apoptosis
Therapy area: Oncology
Developer: Merck & Co. (MRK)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05562830	Phase 1/2	Urothelial Carcinoma	Recruiting	MRK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Urothelial Carcinoma

Other drugs acting on NECTIN4

LY4052031 Phase 1 Sutantatug Envedotin Phase 3

More from Merck &

BCG Live FDA approved Belzutifan FDA approved Berahyaluronidase Alfa FDA approved Berahyaluronidase Alfa and Pembrolizumab FDA approved Enlicitide FDA approved Ensifentrine FDA approved Letermovir FDA approved Pembrolizumab FDA approved Probenecid FDA approved Alimatravir Phase 2 Bomedemstat Phase 2/3 Calderasib Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the MRK page.

Follow MRK, the company behind MK-3120

See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MRK catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z